CE Marked

Implantable Miniature Telescopes
WA IMT 2.2X and WA IMT 3X
(By Dr. Isaac Lipshitz)

CentraSight™
A New Vision for End-Stage AMD

Implantable Telescope Technology





Visit us at
www.CentraSight.com

Designed to Improve Visual Outcomes for Patients with End-Stage AMD

A visual prosthetic device for patients with bilateral, irreversible AMD:

- Designed to improve central vision, critical for activities of daily living and quality of life
- Ultra-precision wide-angle micro-optics creates a telephoto effect to reduce the impact of scotoma
- Intra-ocular implantation allows the patient to use natural eye movements
- 2.2X and 3X Models

Implantation Procedure



12mm limbal incision,
7 mm capsulorhexis



Implantation technique



Secured in capsular bag
for centration



Implanted Eye, 6 week Post-Op

CentraSight Treatment Program

The first-of-kind telescope implant is integral to a new patient care program, CentraSight™, for treating patients with end-stage macular degeneration. The CentraSight treatment program involves a patient management process. The program is conducted by a team of highly trained professionals, each of whom plays a key role in the process. These steps and roles are as follows:

1. Patient Diagnosis and Management: Retina Specialist
2. Low Vision Assessment: Low Vision Professional
3. Implantation: Cornea/Vitreoretinal Surgeon
4. Visual Training/Rehabilitation: Low Vision Professional

The telescope implantation is performed by an eye surgeon as an outpatient procedure. Physicians and patients can find more information about the telescope implant program at **www.CentraSight.com**.

Indication for Use (CE Marked Device)

For improvement of visual acuity in patients with bilateral moderate to profound central vision impairment due to age-related macular degeneration (AMD). Patients selected for implantation should meet the following criteria:

- Patients 55 years of age or older with bilateral, stable, untreatable central vision disorders resulting from AMD as determined by fluorescein angiography, and cataract
- Distance BCVA between 20/80 and 20/800 (6/24 and 6/240), and adequate peripheral vision in one eye (the non-implanted eye) to allow navigation
- Achieve at least a five-letter improvement on the ETDRS chart in the eye scheduled for surgery when using an external telescope
- Planned operative eye must have an anterior chamber depth of 2.5mm
- Patient shows interest in participating in postoperative visual rehabilitation sessions

Refer to www.CentraSight.com for more detailed information about indications and contraindications, directions for use and clinical study results.

VisionCare™
OPHTHALMIC TECHNOLOGIES

VisionCare Ophthalmic Technologies, Inc.
14395 Saratoga Ave., Suite 150, Saratoga, California 95070 USA
Tel: +1 408.872.9393, Fax: +1 408.872.9395, www.visioncareinc.net

The Implantable Miniature Telescope is referred to as "the IMT (by Dr. Isaac Lipshitz)" or as "the Implantable Miniature Telescope (by Dr. Isaac Lipshitz)." This device may be referred to "the product", "the device", "the telescope", "intraocular telescope", or similar terms which cannot be read as the name of the product. VisionCare's Implantable Miniature Telescope was invented by company founders Yossi Gross and Dr. Isaac Lipshitz.

MM02-0003 Rev 0
03/12